The estimated Net Worth of Mitchell J Nelles is at least $2.97 Millón dollars as of 29 June 2018. Mitchell Nelles owns over 39,649 units of Caredx Inc stock worth over $2,478,943 and over the last 10 years Mitchell sold CDNA stock worth over $494,820.
Mitchell has made over 4 trades of the Caredx Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently Mitchell sold 39,649 units of CDNA stock worth $494,820 on 29 June 2018.
The largest trade Mitchell's ever made was selling 39,649 units of Caredx Inc stock on 29 June 2018 worth over $494,820. On average, Mitchell trades about 5,431 units every 49 days since 2015. As of 29 June 2018 Mitchell still owns at least 86,889 units of Caredx Inc stock.
You can see the complete history of Mitchell Nelles stock trades at the bottom of the page.
Mitchell's mailing address filed with the SEC is C/O CAREDX, INC., 3260 BAYSHORE BOULEVARD, BRISBANE, CA, 94005.
Over the last 10 years, insiders at Caredx Inc have traded over $60,271,359 worth of Caredx Inc stock and bought 1,726,634 units worth $9,072,700 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Neil Gagnon y Peter Maag. On average, Caredx Inc executives and independent directors trade stock every 17 days with the average trade being worth of $615,506. The most recent stock trade was executed by Alexander L Johnson on 20 August 2024, trading 61,023 units of CDNA stock currently worth $1,432,820.
caredx: transforming transplant patient care through novel surveillance management solutions caredx, inc. is dedicated to improving the lives of organ transplant patients through non-invasive diagnostics. by combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, caredx is at the forefront of organ transplant surveillance and pre-transplant hla typing solutions. nasdaq:cdna about allosure® allosure is the first and only non-invasive blood test that directly measures allograft injury and identifies the probability of active rejection to better manage kidney transplant patients. allosure is a clinical-grade, proprietary next-generation sequencing (ngs) based test to detect donor-derived cell-free dna (dd-cfdna) in order to identify organ injury in kidney transplant recipients. allosure is analytically validated as a sensitive, specific, and precise measurement of dd-cfdna. allos
Caredx Inc executives and other stock owners filed with the SEC include: